Share ownership Gilead Sciences, Inc.

Equities

GILD

US3755581036

Pharmaceuticals

Real-time Estimate Cboe BZX 19:17:54 13/09/2024 BST 5-day change 1st Jan Change
82.55 USD +0.19% Intraday chart for Gilead Sciences, Inc. +4.70% +1.74%

Share class: Gilead Sciences, Inc.

VoteQuantityFree-FloatCompany-owned sharesTotal Float
Stock A11,244,992,0811,243,417,031 ( 99.87 %) 0 99.87 %

Major shareholders: Gilead Sciences, Inc.

NameEquities%Valuation
Vanguard Fiduciary Trust Co.
9.258 %
115,261,774 9.258 % 9 106 M $
BlackRock Advisors LLC
7.388 %
91,980,274 7.388 % 7 266 M $
Capital Research & Management Co. (World Investors)
6.125 %
76,249,819 6.125 % 6 024 M $
Capital Research & Management Co. (Global Investors)
4.854 %
60,427,714 4.854 % 4 774 M $
State Street Corp.
4.765 %
59,329,915 4.765 % 4 687 M $
Dodge & Cox
2.660 %
33,122,337 2.660 % 2 617 M $
Geode Capital Management LLC
2.166 %
26,966,449 2.166 % 2 130 M $
ishares (DE) Invag Mit Teilgesellschaftsvermogen
2.113 %
26,307,957 2.113 % 2 078 M $
Wellington Trust Co., NA
1.842 %
22,935,083 1.842 % 1 812 M $
Eaton Vance Management
1.553 %
19,337,304 1.553 % 1 528 M $
░░░░░░░░░░░░░░░░░░░░░░░░░░░░ ░ ░░░ ░░░░% ░░
░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░ ░ ░░░ ░░░░% ░░
░░░░░░░░░░░░░░░░░ ░ ░░░ ░░░░% ░░
░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░ ░ ░░░ ░░░░% ░░
░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░ ░ ░░░ ░░░░% ░░
░░░░░░░░░░░░░░░░ ░ ░░░ ░░░░% ░░
░░░░░░░░░░░░░░░░░░░░░░░░░░░░ ░ ░░░ ░░░░% ░░
░░░░░░░░░░░░░░░░ ░ ░░░ ░░░░% ░░
░░░░░░░░░░░░░░░░░░░░░░░░░░░ ░ ░░░ ░░░░% ░░
░░░░░░░░░░░░░░░░░░░░░░░░░░░░ ░ ░░░ ░░░░% ░░
░░░░░░░░░░░░░░░░░░░░░░░░░░░░░ ░ ░░░ ░░░░% ░░
░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░ ░ ░░░ ░░░░% ░░
░░░░░░░░░░░░░░░░░░ ░ ░░░ ░░░░% ░░
░░░░░░░░░░░░░░░░░ ░ ░░░ ░░░░% ░░
░░░░░░░░░░░░░░░░░░░░░░░░░ ░ ░░░ ░░░░% ░░
NameEquities%Valuation
BB Gestão de Recursos DTVM SA
0.000216 %
5,386 0.000216 % 206 004 $
Bram Bradesco Asset Management S/A DTVM
0.000214 %
5,340 0.000214 % 204 244 $

Breakdown by shareholder type

Institutional67.54%
Other10.88%
State Street Corp.4.77%
Manulife Financial Corp.0.53%
Schweizerische Nationalbank0.30%
Sumitomo Mitsui Trust Holdings, Inc.0.24%
Governments0.21%
Swedbank AB0.15%
SEI Investments Co.0.11%
Individuals0.08%
Banco Bilbao Vizcaya Argentaria SA0.05%
Skandinaviska Enskilda Banken AB0.05%
Corebridge Financial, Inc.0.03%
The Bank of Nova Scotia0.03%
ING Groep NV0.02%
Fifth Third Bancorp0.02%
Banque Cantonale Vaudoise0.01%
Nomura Holdings, Inc.0.01%
Cadence Bank0.01%
Atlantic Union Bankshares Corp.0.01%
Zions Bancorporation, NA0.01%
Westpac Banking Corp.0.01%
Ally Financial, Inc.0.01%
Unknown14.92%

Based on 1000 largest holdings

Geographical origin of shareholders

United States 66.50%
United Kingdom 5.23%
Germany 2.49%
Canada 1.92%
Norway 1.58%
France 1.26%
Australia 1.21%
Switzerland 0.84%
Japan 0.64%
Sweden 0.60%
Netherlands 0.58%
Belgium 0.32%
South Korea 0.30%
Luxembourg 0.28%
Denmark 0.22%
Ireland 0.22%
Italy 0.18%
Spain 0.16%
Austria 0.09%
Finland 0.08%
Individuals 0.08%
China 0.06%
Taiwan 0.06%
New Zealand 0.05%
Singapore 0.03%
Czech Republic 0.02%
India 0.02%
Hong Kong 0.02%
Liechtenstein 0.01%
Slovenia 0.01%
South Africa 0.01%
Mexico 0.01%

Based on 1000 largest holdings

Logo Gilead Sciences, Inc.
Gilead Sciences, Inc. specializes in the development, manufacturing and marketing of therapeutic products. Net sales break down by source of income as follows: - sale of drugs (98.9%): for the treatment of HIV (63% of net sales), COVID-19 (20.4%), hepatitis C virus (6.6%), hepatitis B virus (3.6%) and other (6.4%; primarily cytomegalovirus retinitis, and advanced Kaposi sarcoma resulting from HIV); - other (1.1%): especially royalties and revenue from research and development services and from subcontracted production of therapeutic products. Net sales are distributed geographically as follows: the United States (69.2%), Europe (16.4%) and other (14.4%).
Employees
18,000
Calendar
More about the company
-40% Limited Time Offer: Our subscriptions help you unlock hidden opportunities.
BENEFIT NOW